Skip to main content

An Automated Alternative to Traditional NAT Methods

The standard test for mycoplasma contamination is evolving. As macromolecule drugs derived from mammalian cells become more commonplace, reducing the turnaround time for testing and investigation on the large-scale bioreactors of today has become an indispensable need for manufacturers to ensure productivity and cost competency. The pressure to reduce the turnaround time has spurred innovation with real-time PCR methods. The vision for future testing is simple to use, fast and accurate.

Learn more about how Amgen will boost productivity, by adopting the Next Generation Nucleic Acid Amplification Test (NAT), with Chakameh Azimpour, AMGEN Principal Scientist and our own Jeremy Robertson, bioMérieux Global Solution Manager.

 

KEYNOTE SPEAKERS:

  • Chakameh AZIMPOUR, Ph.D. Process Development Principal Scientist, Amgen, Thousand Oaks (California, United States)
  • Jeremy Robertson Global Solution Manager, BIOFIRE, bioMérieux Industrial Microbiology (Chicago, United States)
Please accept targeting cookies to allow Youtube video

FEATURED IN THIS WEBINAR

BIOFIRE® Mycoplasma Nucleic Acid Amplification Technique (NAT)

BIOFIRE® Mycoplasma provides simple, accurate, and rapid in-house mycoplasma detection for use in testing raw materials, in-process samples, and final product release. We offer validation services designed to meet regulatory requirements—from documentation to comprehensive on-site support.

Discover Solution

Interested In Easy At-Line Mycoplasma Testing? Contact Our Experts.

Complete the form below to get in touch with our team. A bioMérieux expert will be in touch using the contact information you provide. By providing your information, you agree to receive additional emails from bioMérieux about mycoplasma testing.

To find out more about the management of your personal data and to exercise your rights, see our privacy policy.